Toll Free: 1-888-928-9744

ActogeniX NV - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

ActogeniX NV - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'ActogeniX NV - Product Pipeline Review - 2014', provides an overview of the ActogeniX NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ActogeniX NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ActogeniX NV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ActogeniX NV's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ActogeniX NV's pipeline products

Reasons to buy

- Evaluate ActogeniX NV's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ActogeniX NV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ActogeniX NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ActogeniX NV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ActogeniX NV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ActogeniX NV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ActogeniX NV Snapshot 5
ActogeniX NV Overview 5
Key Information 5
Key Facts 5
ActogeniX NV - Research and Development Overview 6
Key Therapeutic Areas 6
ActogeniX NV - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
ActogeniX NV - Pipeline Products Glance 12
ActogeniX NV - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
ActogeniX NV - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
ActogeniX NV - Drug Profiles 15
AG-013 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
AG-014 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Cell Therapy for Allergic Disease 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cell Therapy for Type 2 Diabetes 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Genetically Engineered Bacteria for Celiac Disease 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Genetically Engineered Bacteria for Type 1 Diabetes 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Cell Therapy for Undisclosed Indication 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Genetically Engineered Bacteria For Clostridium Difficile Enteropathy 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ActogeniX NV - Pipeline Analysis 23
ActogeniX NV - Pipeline Products by Target 23
ActogeniX NV - Pipeline Products by Route of Administration 24
ActogeniX NV - Pipeline Products by Molecule Type 25
ActogeniX NV - Pipeline Products by Mechanism of Action 26
ActogeniX NV - Recent Pipeline Updates 27
ActogeniX NV - Dormant Projects 28
ActogeniX NV - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31
List of Tables
ActogeniX NV, Key Information 5
ActogeniX NV, Key Facts 5
ActogeniX NV - Pipeline by Indication, 2014 7
ActogeniX NV - Pipeline by Stage of Development, 2014 8
ActogeniX NV - Monotherapy Products in Pipeline, 2014 9
ActogeniX NV - Partnered Products in Pipeline, 2014 10
ActogeniX NV - Partnered Products/ Combination Treatment Modalities, 2014 11
ActogeniX NV - Phase I, 2014 12
ActogeniX NV - Preclinical, 2014 13
ActogeniX NV - Discovery, 2014 14
ActogeniX NV - Pipeline by Target, 2014 23
ActogeniX NV - Pipeline by Route of Administration, 2014 24
ActogeniX NV - Pipeline by Molecule Type, 2014 25
ActogeniX NV - Pipeline Products by Mechanism of Action, 2014 26
ActogeniX NV - Recent Pipeline Updates, 2014 27
ActogeniX NV - Dormant Developmental Projects,2014 28 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify